RCMI Coordinating Center (RCMI CC) Header Logo

Connection

George Perry to Amyloid

This is a "connection" page, showing publications George Perry has written about Amyloid.
Connection Strength

3.224
  1. Rodriguez RA, Chen LY, Plascencia-Villa G, Perry G. Thermodynamics of Amyloid-? Fibril Elongation: Atomistic Details of the Transition State. ACS Chem Neurosci. 2018 04 18; 9(4):783-789.
    View in: PubMed
    Score: 0.603
  2. Rodriguez RA, Chen LY, Plascencia-Villa G, Perry G. Elongation affinity, activation barrier, and stability of A?42 oligomers/fibrils in physiological saline. Biochem Biophys Res Commun. 2017 05 27; 487(2):444-449.
    View in: PubMed
    Score: 0.574
  3. Plascencia-Villa G, Ponce A, Collingwood JF, Arellano-Jim?nez MJ, Zhu X, Rogers JT, Betancourt I, Jos?-Yacam?n M, Perry G. High-resolution analytical imaging and electron holography of magnetite particles in amyloid cores of Alzheimer's disease. Sci Rep. 2016 04 28; 6:24873.
    View in: PubMed
    Score: 0.537
  4. Lee HG, Petersen RB, Zhu X, Honda K, Aliev G, Smith MA, Perry G. Will preventing protein aggregates live up to its promise as prophylaxis against neurodegenerative diseases? Brain Pathol. 2003 Oct; 13(4):630-8.
    View in: PubMed
    Score: 0.225
  5. Smith MA, Nagaraj RH, Perry G. Protocol for quantitative analysis of paired helical filament solubilization: a method applicable to insoluble amyloids and inclusion bodies. Brain Res Brain Res Protoc. 1997 Aug; 1(3):247-52.
    View in: PubMed
    Score: 0.147
  6. Smith MA, Perry G. The pathogenesis of Alzheimer disease: an alternative to the amyloid hypothesis. J Neuropathol Exp Neurol. 1997 Feb; 56(2):217.
    View in: PubMed
    Score: 0.142
  7. Hou L, Lee HG, Han F, Tedesco JM, Perry G, Smith MA, Zagorski MG. Modification of amyloid-?1-42 fibril structure by methionine-35 oxidation. J Alzheimers Dis. 2013; 37(1):9-18.
    View in: PubMed
    Score: 0.107
  8. Kawai M, Kalaria RN, Harik SI, Perry G. The relationship of amyloid plaques to cerebral capillaries in Alzheimer's disease. Am J Pathol. 1990 Dec; 137(6):1435-46.
    View in: PubMed
    Score: 0.092
  9. Cras P, Kawai M, Siedlak S, Mulvihill P, Gambetti P, Lowery D, Gonzalez-DeWhitt P, Greenberg B, Perry G. Neuronal and microglial involvement in beta-amyloid protein deposition in Alzheimer's disease. Am J Pathol. 1990 Aug; 137(2):241-6.
    View in: PubMed
    Score: 0.090
  10. Perry G, Siedlak S, Mulvihill P, Kancherla M, Mijares M, Kawai M, Gambetti P, Sharma S, Maggiora L, Cornette J, et al. Immunolocalization of the amyloid precursor protein within the senile plaque. Prog Clin Biol Res. 1989; 317:1021-5.
    View in: PubMed
    Score: 0.081
  11. Castellani RJ, Lee HG, Siedlak SL, Nunomura A, Hayashi T, Nakamura M, Zhu X, Perry G, Smith MA. Reexamining Alzheimer's disease: evidence for a protective role for amyloid-beta protein precursor and amyloid-beta. J Alzheimers Dis. 2009; 18(2):447-52.
    View in: PubMed
    Score: 0.081
  12. Perry G, Lipphardt S, Mulvihill P, Kancherla M, Mijares M, Gambetti P, Sharma S, Maggiora L, Cornette J, Lobl T, et al. Amyloid precursor protein in senile plaques of Alzheimer disease. Lancet. 1988 Sep 24; 2(8613):746.
    View in: PubMed
    Score: 0.079
  13. Castellani RJ, Smith MA, Perry G, Friedland RP. Cerebral amyloid angiopathy: major contributor or decorative response to Alzheimer's disease pathogenesis. Neurobiol Aging. 2004 May-Jun; 25(5):599-602; discussion 603-4.
    View in: PubMed
    Score: 0.058
  14. H?ilund-Carlsen PF, Alavi A, Barrio JR, Castellani RJ, Costa T, Herrup K, Kepp KP, Neve RL, Perry G, Revheim ME, Robakis NK, Sensi SL, Vissel B. Revision of Alzheimer's diagnostic criteria or relocation of the Potemkin village. Ageing Res Rev. 2024 01; 93:102173.
    View in: PubMed
    Score: 0.057
  15. H?ilund-Carlsen PF, Revheim ME, Costa T, Alavi A, Kepp KP, Sensi SL, Perry G, Robakis NK, Barrio JR, Vissel B. Passive Alzheimer's immunotherapy: A promising or uncertain option? Ageing Res Rev. 2023 09; 90:101996.
    View in: PubMed
    Score: 0.055
  16. Aliev G, Smith MA, Obrenovich ME, de la Torre JC, Perry G. Role of vascular hypoperfusion-induced oxidative stress and mitochondria failure in the pathogenesis of Azheimer disease. Neurotox Res. 2003; 5(7):491-504.
    View in: PubMed
    Score: 0.053
  17. H?ilund-Carlsen PF, Alavi A, Perry G, Barrio JR. MRI Monitoring of Anti-Alzheimer Therapy Amyloid-Related Imaging Abnormalities: Due Diligence or Overkill? AJNR Am J Neuroradiol. 2023 01; 44(1):E4-E5.
    View in: PubMed
    Score: 0.053
  18. Perry G, Siedlak SL, Richey P, Kawai M, Cras P, Kalaria RN, Galloway PG, Scardina JM, Cordell B, Greenberg BD, et al. Association of heparan sulfate proteoglycan with the neurofibrillary tangles of Alzheimer's disease. J Neurosci. 1991 Nov; 11(11):3679-83.
    View in: PubMed
    Score: 0.025
  19. Tabaton M, Perry G, Zhu X, Lee HG, Casadesus G, Smith MA. Memantine: "hypothesis testing" not "disease modifying" in Alzheimer's disease. Am J Pathol. 2010 Feb; 176(2):540-1.
    View in: PubMed
    Score: 0.022
  20. Tabaton M, Mandybur TI, Perry G, Onorato M, Autilio-Gambetti L, Gambetti P. The widespread alteration of neurites in Alzheimer's disease may be unrelated to amyloid deposition. Ann Neurol. 1989 Dec; 26(6):771-8.
    View in: PubMed
    Score: 0.022
  21. Palmert MR, Siedlak SL, Podlisny MB, Greenberg B, Shelton ER, Chan HW, Usiak M, Selkoe DJ, Perry G, Younkin SG. Soluble derivatives of the beta amyloid protein precursor of Alzheimer's disease are labeled by antisera to the beta amyloid protein. Biochem Biophys Res Commun. 1989 Nov 30; 165(1):182-8.
    View in: PubMed
    Score: 0.022
  22. Autilio-Gambetti L, Morandi A, Kovacs DM, Tabaton M, Schaetzle B, Hauer C, Groger RK, Tykocinski ML, Perry G, Greenberg BD, et al. Amyloid precursor protein in cell cultures: a 130 kDa polypeptide. Prog Clin Biol Res. 1989; 317:985-90.
    View in: PubMed
    Score: 0.020
  23. Autilio-Gambetti L, Morandi A, Tabaton M, Schaetzle B, Kovacs D, Perry G, Sharma S, Cornette J, Greenberg B, Gambetti P. The amyloid percursor protein of Alzheimer disease is expressed as a 130 kDa polypeptide in various cultured cell types. FEBS Lett. 1988 Dec 05; 241(1-2):94-8.
    View in: PubMed
    Score: 0.020
  24. Forero DA, Casadesus G, Perry G, Arboleda H. Synaptic dysfunction and oxidative stress in Alzheimer's disease: emerging mechanisms. J Cell Mol Med. 2006 Jul-Sep; 10(3):796-805.
    View in: PubMed
    Score: 0.017
  25. Webber KM, Raina AK, Marlatt MW, Zhu X, Prat MI, Morelli L, Casadesus G, Perry G, Smith MA. The cell cycle in Alzheimer disease: a unique target for neuropharmacology. Mech Ageing Dev. 2005 Oct; 126(10):1019-25.
    View in: PubMed
    Score: 0.016
  26. Zhu X, Raina AK, Perry G, Smith MA. Alzheimer's disease: the two-hit hypothesis. Lancet Neurol. 2004 Apr; 3(4):219-26.
    View in: PubMed
    Score: 0.015
  27. Pappolla MA, Smith MA, Bryant-Thomas T, Bazan N, Petanceska S, Perry G, Thal LJ, Sano M, Refolo LM. Cholesterol, oxidative stress, and Alzheimer's disease: expanding the horizons of pathogenesis. Free Radic Biol Med. 2002 Jul 15; 33(2):173-81.
    View in: PubMed
    Score: 0.013
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
RCMI CC is supported by the National Institute on Minority Health and Health Disparities, National Institutes of Health (NIH), through Grant Number U24MD015970. The contents of this site are solely the responsibility of the authors and do not necessarily represent the official views of the NIH

For technical support please contact support